27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Moderna Inc (NASDAQ:MRNA)'s CEO said last week that it will not seek emergency use authorization for its coronavirus vaccine candidate mRNA-1273 before the Nov. 3 U.S. presidential election.
Trial Enrollment Hits 94% Of Target: Moderna's vaccine candidate is in a large-scale Phase 3 trial dubbed COVE with a target enrollment of 30,000 participants.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
About 28,043, or 93.5%, of the targeted participants have been enrolled into the study, Moderna said in a late Friday tweet.
Of those people, 19,369 have been administered a second dose.
As of Friday, October 2, 2020, 28,043 participants have been enrolled in the Phase 3 COVE study and approximately 33% of participants enrolled cumulatively are from diverse communities. 19,369 participants have received their second vaccination. https://t.co/ToJWTx59PI pic.twitter.com/dR3r19CKav
— Moderna (@moderna_tx) October 2, 2020
The study protocol calls for administering two doses of mRNA-1273 — the first on day one and the second on day 29.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
About 33% of the participants were from diverse communities, Moderna said. The company announced the dosing of the first patient in the trial on July 27.
See also: The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO
Slowing Enrollment Behind The Delay? Moderna's muted expectations concerning an expedited rollout under an emergency use authorization is partly attributable to the slowdown in enrollment in recent weeks, according to one sell-side analyst.
"Moderna's slower enrollment rate (partially due to an effort to include more diverse demographics) will likely push their earliest possible timeline for positive first interim efficacy readout until after the U.S. election," Raymond James analyst Steven Seedhouse said in a note.
The analyst said he expects Pfizer Inc. (NYSE:PFE)/BioNTech SE – ADR (NASDAQ:BNTX) to be first with an interim efficacy readout before the election and probably before the Oct. 22 general vaccine Adcom meeting.
Hard numbers substantiate the conjecture concerning the reason for the potential delay in Moderna's vaccine program.
Nov. 25 is likely the date when enough safety data will become available to be included in an emergency use authorization application, Moderna CEO Stéphane Bancel told the Financial Times last week.
MRNA Price Action: Moderna shares gained 4.56% in Monday's session, closing at $71.95.
Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.